Huons extends contract to exclusively distribute Biosyn's selenium deficiency treatment in Korea

Huons said it has recently renewed its agreement with Biosyn Korea, the Korean offshoot of Biosyn Arzneimittel GmbH, a German pharmaceutical company, for the exclusive domestic distribution rights of Selenase, a selenium deficiency treatment.

This agreement is an extension of the existing exclusive domestic sales contract for Selenase signed by the two companies in 2013.

Under the renewed accord, Huon's will have exclusive domestic distribution rights for Selenase until 2028.

"We are pleased to have secured the continued exclusive distribution rights for Selenase in Korea," a Huons official said. "We will continue to expand the supply of Selenase and contribute to the improvement of public health."

Selenase is a medication for the treatment of selenium deficiency. It was first launched in 1987 by Biosyn and is currently a blockbuster item with annual sales of 12 billion won ($9 million) as of 2022.